Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Albany Molecular Research Inc announces early termination of HSR waiting period for acquisition of Oso Biopharmaceuticals Manufacturing


Monday, 23 Jun 2014 08:00am EDT 

Albany Molecular Research Inc:Says in connection with AMRI's proposed acquisition of Oso Biopharmaceuticals Manufacturing, LLC (OsoBio) was terminated by the United States Federal Trade Commission on June 20.Previously announced on June 2 AMRI entered into definitive agreement to acquire all of the outstanding membership interests of OsoBio for $110 mln in cash.Says early termination of the HSR waiting period satisfies one of the conditions to the proposed acquisition.Subject to satisfaction of other customary closing conditions, the transaction is expected to be completed in the third quarter of 2014. 

Company Quote

22.45
0.59 +2.70%
21 Oct 2014